Date:8/16/2010

r ENMD-2076 in ovarian cancer patients.  The Phase 2 study is being conducted at six prestigious cancer centers within the U.S. and Canada and all sites are currently enrolling patients.  In addition, we regained compliance with the minimum bid price rule and maintained our listing on the NASDAQ Capital Market.  Early in the second quarter we completed our third financing for 2010 for $3.0 million in gross proceeds.  We remain encouraged and enthusiastic about the progress of the ENMD-2076 clinical program and are working hard to meet our development objectives for this exciting compound."

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound's applicability in other forms of cancer.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in
'/>"/>

SOURCE EntreMed, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
2. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
3. EntreMed Presents Initial Clinical Results for ENMD-2076
4. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
5. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
6. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
7. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
8. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
9. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
10. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
11. EntreMed to Present at The New York Society of Security Analysts Industry Conference